“It’s no surprise that COVID-19 negatively impacted Americans’ health and the extreme two-month sleep shift is alarming,” said Mary Helen Rogers, vice president of marketing and communications for the Better Sleep Council.

ALEXANDRIA, Va. (PRWEB)
April 27, 2020

The BSC launched wave two of “The State of America’s Sleep” in January 2020, but then completed another round of research in March 2020, to compare sleep habits during the COVID-19 pandemic. Themes such as spikes in stress, health worries and economic concerns emerged from the study:

1. Stress Skyrockets:

• In January 2020, four in 10 (41%) Americans reported feeling stressed often or very often. As of March, over half Americans (53%) felt stressed about COVID-19 often or very often.

2. Sleep Suffers:

• In January 2020, 54% of Americans were getting the minimum 7-8 hours of recommended sleep. As of March, fewer than half (49%) did.
• Similarly, in January 2020, over four in 10 Americans described their sleep as poor or fair (43%). As of March, over half of the nation qualified their sleep as poor or fair (52%).

3. Economic Woes:

• About one-third of the nation felt good about the economy in January 2020 (38%) vs. less than 20% did as of March 2020.
• Lack of confidence in the stock market prevailed in the nation in March (56% of Americans disagree that they have confidence in the stock market vs. 39% in January 2020).

“It’s no surprise that COVID-19 negatively impacted Americans’ health and the extreme two-month sleep shift is alarming,” said Mary Helen Rogers, vice president of marketing and communications for the Better Sleep Council. “However, if we take our findings and help Americans unwind and sleep better during this pandemic, we’ll fulfill our role as the Guardians of America’s Sleep.”

About the BSC

The Better Sleep Council is the consumer-education arm of the International Sleep Products Association, the trade association for the mattress industry. With decades invested in improving sleep quality, the BSC educates consumers on the link between sleep and health, and the role of the sleep environment, primarily through http://www.bettersleep.org, partner support and consumer outreach.

###

Share article on social media or email:

FREDERICK, Md. (PRWEB)
April 27, 2020

Mesa Science Associates Inc. (MSA) and Bryn Pharma LLC published the findings from the second of three (3) pre-clinical studies conducted in beagle dogs. These studies establish that epinephrine is readily absorbed when administered intranasally and has advantages over an intramuscular injection of epinephrine. The pre-clinical study was managed by MSA and was conducted at MRI Global Laboratories in Kansas City, MO. The study was funded by Bryn Pharma LLC of Raleigh, NC. The study was published in Pharmacology Research and Perspectives and is entitled Intranasal Epinephrine in dogs: Pharmacokinetic and heart rate effects.

The second study found that epinephrine administered intranasally was well-tolerated and had advantages when compared to epinephrine via auto-injector (intramuscularly). Intranasal epinephrine administration resulted in a more rapid increase in plasma epinephrine concentration within the first five minutes and produced less increases in heart rate over time when compared to intramuscular injection.

This study involved single doses of intranasal epinephrine given to dogs in doses of 2, 3, 4, 5, 10 and 20 mg. Intramuscular administration of epinephrine was given at doses of either 0.15 or 0.3 mg to the bicep of the dogs using an autoinjector. Three plasma samples were collected before dosing, and after administration at the intervals of 1, 5, 10, 15, 20, 30, 60, and 90 minutes. Electrocardiogram measurements were also used to monitor and record the heart rates at the same intervals. No anesthesia was required for administration of the doses. Increasing intranasal dosing from 2 to 20 mg resulted in a dose-related increase in plasma concentrations of the drug. No significant adverse effects were noted in the dose range of 2 to 10 mg. An intranasal dose of 2 mg produced plasma levels that were similar to those observed with 0.15 mg given by intramuscular administration. Similarly, 4 and 5 mg intranasally resulted in plasma levels that closely approximated the intramuscular administration of 0.3 mg.

Dogs are an advantageous species for clinical translation (pre-human trials) because of the similarities in the nasal environment of dogs and humans. These include similar nasal volume, dimension, surface area, and clearance. During the course of the three canine studies no animals we injured and at the conclusion of the studies all animals were adopted into forever homes.

The overall study offers an alternate route of administration for epinephrine, via the nostril, reducing the anxieties that come along with an auto-injector and the associated hypodermic needle injection. There are known advantages of intranasal administration, but the literature regarding its use is limited. Intranasal administration of epinephrine could lead to increased usage versus an auto-injector, with less hesitation for use in patients with severe allergies.

Anaphylaxis is a serious and sometimes life-threatening allergic reaction where the immune system overreacts to an allergen by releasing histamines that cause allergy symptoms. In severe cases if anaphylaxis isn’t properly treated, it can be fatal. Rates of such reactions have increased over the last 20 years and are usually treated by administering epinephrine into a muscle with an auto-injector.

Michael Mesa, CEO of Mesa Science Associates, is anticipating the publication of the last of three (3) studies this spring. These pre-clinical studies preceded human studies which were started in 2019 and are planned for completion over the coming summer. The planned clinical studies will further investigate intranasal epinephrine pharmacokinetic and pharmacodynamic effects. Mr. Mesa stated that “These study results are the cumulation of effective partnering with Bryn Pharma and Mesa Science Associates and is just another example of the exceptional achievements that have resulted from effective collaboration between our two companies on this program.” He also noted that “during the conduct of these studies no animal was injured and all study animals were adopted into forever homes.”

In addition to the pre-clinical studies, MSA continues to provide support for Bryn Pharma nasal product development activities including device activities, identification of a contract fill and finish source, and coordination with the fill and finish source for Chemistry, Manufacturing and Controls activities. MSA also utilizes its extensive list of pharmaceutical experts to provide advice on a variety of manufacturing, clinical, quality, technical and scientific issues.

Mesa Science Associates is a pharmaceutical product development company located inside the Frederick Innovation and Technology Center Inc. (FITCI) in Frederick, MD. The mission of the company is to provide technical and scientific expertise to researchers from all aspects of the drug, drug delivery and product development community, including researchers from government, academia, as well as private entities.

For more information on Mesa Science Associates visit http://www.mesascience.com/

Share article on social media or email:

“We want to say thank you to all the brave and talented frontline healthcare workers helping to fight the global COVID-19 crisis.”

TROY, Mich. (PRWEB)
April 27, 2020

Employment BOOST is saying thank you to frontline healthcare workers by assisting family members whose jobs have been affected by the coronavirus pandemic and offering free 5-star-rated professional resume writing and job search assistance. Employment BOOST has committed $10,000 worth of resources as part of the initiative.

Until June 30, individuals can call into (888) 468-6495 to speak with the Employment BOOST team and sign up for the free packages.

One of the highest-rated professional career services firms in the country, Employment BOOST’s free resume writing packages will include:

• 
  One-on-one consultation with a Certified Professional Resume Writer
• Brand new professional resume
• Customizable cover letter
• LinkedIn profile development
• Complimentary thank you letter

“We want to say thank you to all the brave and talented frontline healthcare workers helping to fight the global COVID-19 crisis,” said William Ratliff, Senior Career Services Manager at Employment BOOST. “Knowing how fragile the job market is at the moment, the least we can do as career services professionals is lend a helping hand the best way we know how.”

With more than a decade of career services experience, Employment BOOST’s professional resume writing services begin with a one-on-one consultation with a Certified Professional Resume Writer, who will guide the process of creating a brand-new polish professional resume, cover letter, LinkedIn profile, and thank you letter. Employment BOOST has offices in Michigan, Illinois, Colorado, New York, and Ohio. The services will be conducted over the phone or teleconference.

“We understand how difficult and stressful it is to look for a job in any market, let alone a global pandemic,” said Dennis Theodorou, Managing Director of Employment BOOST. “We encourage anyone who is having difficulty with their job search to reach out and take advantage of these free resume writing packages. We want to help those who are risking everything for the rest of us.”

Individuals looking to access the free professional resume writing packages can call into (888) 468-6495 to speak with the Employment BOOST team and sign up.

About Employment BOOST:

Employment BOOST is a Troy, Michigan and Chicago, Illinois based company that provides professional resume writing services and critiquing, executive resume services, cover letter development, resume distribution, social media profile creation, and interview coaching to job seekers across the nation. For more than a decade, Employment BOOST has consistently been helping people achieve career satisfaction. Employment BOOST uses talented industry experts to tailor resumes to the key content that hiring managers seek. For more information on Employment BOOST, please call 888-468-6495 or visit https://employmentboost.com.

Share article on social media or email:

Atlantic Data Forensics, Inc.

ELKRIDGE, Md. (PRWEB)
April 27, 2020

In response to an unprecedented increase in ransomware and data breach activity during the COVID-19 pandemic, Atlantic Data Forensics, Inc. announced today that it will provide Digital Forensics/Incident Response (DFIR) services to US-based healthcare organizations and first responders whose COVID-19 related patient care and other front-line systems have been compromised by cybercriminal activity.

During this time of disruption, emergency expansion and resource limitation for healthcare providers dealing with the impact of COVID-19, cybercriminals have stepped up their attacks on those same providers through phishing and probing networks in an effort to profit from disabling hospital computer systems through ransomware, stealing patient healthcare data or furthering financial fraud schemes.

Last week the FBI reported through their Internet Crimes Complaint Center (IC3), that since the beginning of the COVID-19 pandemic, the Bureau has seen the number of incidents reported increase from 1,000 per day to upwards of 4,000. Likewise, Atlantic Data Forensics has responded to a significant increase of cybersecurity incidents due to increased cybercriminal activity during the pandemic.

“After looking at current cyber threat intelligence and our own surge in incident response activity, I realized the company could help by providing free services to not only our healthcare clients that are under increased attack, but to all healthcare organizations currently on the front lines of this battle.” said Brian Dykstra, CEO, of Atlantic Data Forensics, “I chose to present this offering to the healthcare community because, like many other people, I’ve been challenged in trying to find a way to contribute and directly assist health care professionals during this pandemic.”

Atlantic Data Forensics has a team of experienced, computer incident responders and computer forensic examiners that are the choice of many of the nation’s largest businesses, law firms, government agencies and non-profit organizations.

If you would like more information about this topic, please call Patrick Wynn at (410) 540-9000 x110 or email contact@atlanticdf.com

Share article on social media or email: